Reply: SARS-CoV-2 vaccination in inflammatory bowel disease patients with different biological agents.
Rev Esp Enferm Dig
; 115(10): 584, 2023 Oct.
Article
en En
| MEDLINE
| ID: mdl-36633163
ABSTRACT
We thank Dr Mungmunpuntipantip and colleague for their interest and thoughtful comments on our publication. The authors have highlighted several important considerations for the impact of SARS-CoV-2 vaccination in inflammatory bowel disease (IBD) patients with different biological agents. We fully agree with the author's point of view, and we also point out the limitations in our meta-analysis.
Texto completo:
1
Banco de datos:
MEDLINE
Idioma:
En
Año:
2023
Tipo del documento:
Article